You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  3. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Continuous Monitoring of COVID-19 Symptomatology for Elderly Patients in Long Term Care Facilities Using Advanced, Soft, and Flexible Sensors Mounted on the Suprasternal Notch

    SBC: Sonica LLC            Topic: NIA

    PROJECT SUMMARY: COVID-19 is significantly more lethal in the elderly1 with the greatest risk in those cared for in long-term care facilities (LTCs) where mortality rates range from 19% to 72% worldwide. Monitoring COVID-19 infections in LTCs remains a particular challenging. The existing and a continued expected shortage of sufficient molecular COVID-19 testing coupled to false negative rates as ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy

    SBC: Enzyme by Design Inc.            Topic: 102

    PROJECT SUMMARY Enzyme by DesignIncEbDis developing a safer version of L asparaginase that can be used routinely in the treatment of adult ALL patients whose hypersensitivity to todayandapos s bacterial L asparaginases deprives them from this efficacious therapyEbDandapos s L asparaginase is novel due to its mammalianguinea pigorigin and its lack of L glutaminase co activityThe need for better the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary Abstract Kidney stonesKSare highly prevalentexcruciatingand associated with long term complications of chronic kidney diseaseCKDand end stage renal diseaseESRDThey account forM ER visits and andgt $B of medical costs annually and have a striking recurrence rate ofinyears and up toinyearsreflecting the inadequacies of current interventionsof KS are composed of calcium oxalate and sm ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel safe and efficacious biologic drug for the treatment of AML

    SBC: Enzyme by Design Inc.            Topic: O

    PROJECT SUMMARY There is a clear unmet need for effective treatments for acute myeloid leukemiaAMLAn exciting new mechanism for targeting cancer cells involves the activation of the extrinsic apoptotic pathway by administering the soluble domain of TNF related apoptosis inducing ligandTRAILcalled dulanerminMuch hope has been placed on this drug since TRAIL has been shown to bind to death receptors ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

    SBC: HEALTHCHART LLC            Topic: 102

    Project Summary Abstract Peripheral T cell lymphomaPTCLis a heterogeneous cancer that constitutes up toof all non Hodgkin lymphomaNHLThe World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologistsFurthermoreof PTCL cases are not classifiable into any specific subtype at all ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government